The use of neutralizing anti-VEGFβ and anti-IL-17 antibodies in mice with DKD generated a decrease in the inflammatory reaction and renal fibrosis, as well as in renal lipid deposits, predominantly triglycerides [72]. The gene discussed is VEGFB; the disease is renal fibrosis.